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Treatment of human immunodeficiency virus type 1 (HIV-1)-infected patients with combination drug regimens results in a
reduction of plasma viral load to levels below the limit of detection. To investigate the genomic fluctuations in HIV-1
populations from long-term responders to antiviral therapies we analyzed the viral sequence evolution of env and pol genes
from sequential peripheral blood mononuclear cell (PBMC) DNA samples of three infected patients. Analyses of sequences
covering the V3 and flanking env regions obtained from blood samples at the beginning of the therapy and at 14 or 24 months
from baseline revealed that HIV-1 quasispecies continue to evolve in the three patients following combination antiretroviral
therapy. Minor drug-resistant mutant subpopulations were also searched for and found in one patient. Interestingly, no minor
resistant subpopulations were found in the other two patients despite the fact that they showed evidence of ongoing viral
replication. Finally, the genetic analysis of the env gene shows a reduction in PBMC env viral population diversity after
long-term response to the therapy in all the patients analyzed. © 1999 Academic Press
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tIntroduction. The introduction of different combination
rug regimens has allowed the reduction of plasma viral
oad to levels below the limit of detection for more than
wo years in human immunodeficiency virus type 1 (HIV-
)-infected patients (1, 11). Although initially a mathemat-
cal model has suggested that 2.3–3.1 years of complete
iral replication suppression could eradicate the HIV-1
nfection (20), recently the presence of HIV-1 DNA and an
nducible latent viral reservoir in peripheral blood mono-
uclear cells (PBMCs) and lymph nodes (LNs) has been
ocumented, despite prolonged suppression of plasma
iremia (4, 5, 27, 28). It is controversial whether active
irus replication is ongoing in patients with a prolonged
ndetectable plasma HIV RNA. Evidence for viral repli-
ation in the LNs has been observed in patients with
ndetectable plasma HIV RNA (3, 22). Additionally, the
resence of unintegrated HIV-1 DNA in infected resting
D41 T cells in patients with less than 500 copies of HIV
NA/ml of plasma has been shown to illustrate active
irus replication in those individuals (4). In contrast, com-
lete suppression of viral replication, after 1 year of triple
herapy, has been suggested by the fact that population-
ased sequencing of HIV pol showed high sequence
omology to the sequences obtained at baseline (28).
urthermore, evolving genotypic drug resistance or the
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180resence of multiple spliced RNA have been docu-
ented in patients with plasma HIV RNA levels between
0 and 400 copies/ml, but not in patients with less than
0 copies of plasma HIV RNA/ml (12). However, HIV-1
opulations were not genetically analyzed at their most
ariable locus, the envelope (env) gene.
Recently, rapid, transient changes at the env locus
uring the emergence of protease inhibitor resistance
ave been documented (5), but data about the genetic
hanges observed in long-term responder patients to
ntiretroviral therapy is lacking. In this paper, we report
he genetic changes observed in the viral populations
fter the bottleneck originated by the drugs in long-term
esponders to different antiretroviral therapies. For this
urpose, sequences representing the V3 and flanking
nv regions were isolated from PBMCs at baseline and
t 24 (patients A and B) or 14 (patient C) months of
ntiretroviral therapy and the diversity of the quasispe-
ies were analyzed. Partial sequencing of HIV pol qua-
ispecies was also carried out to compare the evolution
ate of both genes and to detect emergence of genotypic
rug resistance. Phylogenetic reconstructions of the env
equences showed that despite the lower genetic het-
rogeneity observed after the therapy HIV-1 continues to
eplicate in the three patients analyzed. Analysis of pol
equences identified minority single resistance substitu-
ions in one patient.
Results. We have previously described a partial im-
une restoration in a group of nine HIV-1-infected pa-
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181RAPID COMMUNICATIONients, under antiretroviral combination therapy with nu-
leoside analogues, who maintained undetectable HIV-1
NA plasma levels for more than 24 months (1). We
racked the evolution of viral sequences in HIV-1 popu-
ations obtained from sequential blood samples from two
f these individuals and from another patient under triple
ombination therapy that included a protease inhibitor
Fig. 1). Phylogenetic analysis of these sequences re-
ealed distinct clusters of viral sequences for each pa-
ient, indicating the absence of polymerase chain reac-
ion (PCR) product cross-contamination (Fig. 2). Addition-
lly, no closely matched sequences were found when
epresentative viral sequences from each individual
ere compared to the GenBank HIV sequence database
sing the BLAST program (13). The V3 env neighbor-
oining tree shown in Fig. 2A revealed, for patients A and
, distinct, temporal clustering of sequences at each
ime point. This pattern is indicative of continuous qua-
ispecies evolution in these two individuals. We hypoth-
sized that in the absence of viral replication no viral
volution might be observed and, therefore, no signifi-
ant divergence in the V3 sequences should be de-
ected. In contrast, the phylogenetic reconstruction for
atient C showed an intermingling of sequences from
he two time points. Visual inspection of this neighbor-
oining tree suggested a trend toward decreasing ge-
etic diversity of the V3 env quasispecies after a pro-
onged period of plasma viremia suppression. This trend
as quantitatively evaluated by calculating the intra-time
oint sequences’ distances. Mean intra-time point dis-
ances are shown in Table 1. The DNA distances at the
eginning of the therapy and at 24 or 14 months of
ntiretroviral therapy were compared by the Wilcoxon
FIG. 1. Summary of CD4 T-cell counts and quantitative HIV-1 virion-a
fter the beginning of the therapy is annotated on the abscissa. CD4 T-c
er microliter of blood. HIV-1 RNA levels were measured by a quantitat
xpressed per mililiter of plasma. The time in months when sequencing
, and 0 and 14 months for patient C. Specific antiretroviral therapiesigned rank test (Table 1). All patients showed a statis- rically significant decrease in DNA sequence variation
uring this period (P 5 0.001, P , 0.001, and P , 0.001 for
atients A, B, and C, respectively).
To screen for positive selection within the V3 and
lanking env regions, the synonymous and nonsynony-
ous nucleotide pattern was also analysed (Table 1). We
erived the mean number of synonymous substitutions
ds) per potential synonymous site and of nonsynony-
ous substitutions (dn) per potential nonsynonymous
ite for all pairwise comparisons of sequences of the
hree patients in the two samples taken at the beginning
f the therapy and at 24 or 14 months of therapy (Table 1).
he ratios of synonymous to nonsynonymous base sub-
titutions (ds/dn) for these three subjects at the begin-
ing of the therapy was 0.3, 0.8, and 0.6 respectively
Table 1), suggesting a positive selection for change in
his region. As described by others (2, 26), this pattern
grees well with the clinical status and CD4 cell count of
he three patients. Interestingly, the ds/dn ratios after the
herapy were significantly different (P , 0.001, P 5 0.001,
nd P , 0.001, respectively) from the baseline ratios and
reater than 1.0:1.8, 1.0:2.1, and 1.0:2.2 for patients A, B,
nd C, respectively. These results showed either a dif-
erent selection pressure or different quasispecies con-
traints for change after a long period of viral plasma
uppression.
To search for minor drug-resistant mutant subpopula-
ions selected by the antiretroviral combination therapy,
e carried out within the first 238 aa of the reverse
ranscriptase (RT) region a similar clonal analysis to that
erformed in the V3 and flanking env regions (Fig. 2B). In
ne subject, patient A, it was possible to identify, after
he therapy, one clone out of eight with the 3TC-selected
ed RNA for each of the three infected patients (A through C). The time
nts were measured by flow-activated cytometric assay and expressed
rse transcription–PCR assay (Roche Molecular Systems, Inc.) and are
rformed was 0 and 24 months for patient A, 0 and 24 months for patient
ir duration are highlighted above each graph.ssociat
ell cou
ive reve
was peesistant substitution M184V (Fig. 2B). Thus, emergence
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182 RAPID COMMUNICATIONf drug-resistant substitutions is not prohibited after 24
onths of suppressive antiretroviral therapy. No minor
FIG. 2. Neighbor-joining phylogenetic tree of proviral sequences from
B) RT pol sequences. Filled symbols represent the initial time point; ope
rug resistance-associated mutations are indicated. Triangles represen
olecular endpoints from PCR. Numbers at branch nodes refer to the n
ogether; only those occurring at a frequency greater than 80% are shesistant mutant subpopulations were found within the fther two patients (Fig. 2B). As expected, mean intra-time
oint sequence distances at baseline were two- to three-
ood of the three patients analyzed in this study. (A) V3 env sequences.
ols are sequences from the final time point. RT pol sequences bearing
ences from cloned PCR product; circles are from direct sequencing of
of bootstrap repetitions (of 100) at which the distal sequences groupedthe bl
n symb
t sequ
umberold lower than those of V3 and flanking env regions
(
o
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183RAPID COMMUNICATIONTable 2) (21). A decrease in sequence distance was also
bserved when DNA sequence distances at baseline
nd after therapy were compared, although now statis-
ical significance was only reached for one of three
FIG. 2atients (Table 2). rDiscussion. In this study, we characterized the viral
equence variation over time in the PBMCs from three
ong-term responders to antiretroviral combination ther-
pies who presented plasma virus concentrations in the
inuedange of 20–200 copies. Despite the fact that viral RNA in
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184 RAPID COMMUNICATIONlasma is not completely suppressed and therefore the
lasma RNA data would seem sufficient to assess that
iral replication is ongoing in these patients, the analysis
f virus sequence evolution over time is a useful adjunct
o determining the extent and durability of sustained
uppression of viral replication. In fact, we have shown
hat the HIV-1 quasispecies continue to evolve and that
mergence of drug-resistant substitutions is observed in
ne patient (A) (Fig. 2B). However, the majority of the pol
equences in this patient are wild type (WT), suggesting
hat the replication of the WT viruses are not entirely
estrained. Of note, the other two patients did not show
ny genotypic drug resistance despite low-level viral
eplication during a long period of time. These findings
ave important implications because evolving genotypic
rug resistance is expected in patients with low-level
iral replication. The small viral-effective population size
odel, in which chance plays a significant role (15, 16),
as been suggested to provide an explanation for the
T
Intra-Time Point Distances for V3 an
atient
Sampling time
(months after
therapy) nb
DNA distance
(mean 6 SD)
Wilcoxon’s
signed rank
testc
Mean
6 S
A 0 9 4.0 6 1.8 0.001 1.4 6
24 10 2.1 6 1.9 2.0 6
B 0 12 7.5 6 3.6 ,0.001 5.9 6
24 14 1.2 6 1.3 1.9 6
C 0 12 4.6 6 2.5 ,0.001 2.5 6
14 14 3.2 6 1.9 4.1 6
a Intra-time point comparisons of synonymous substitutions per pot
onsynonymous site (dn) and the ratio of synonymous to nonsynonym
ous substitution (i.e., dn 5 0) was not included in the calculation.
b Number of clones analyzed.
c P value.
T
Intra-Time Point Distances fo
atient
Sampling time
(months after
therapy) nb
DNA distance
(mean 6 SD)
Wilcoxon’s
signed rank
testc
Mean
6 S
A 0 16 1.4 6 0.4 0.952 4.0 6
24 8 1.4 6 0.6 4.3 6
B 0 8 1.6 6 0.4 0.001 4.6 6
24 13 1.1 6 0.5 4.3 6
C 0 7 1.9 6 0.6 0.444 5.7 6
14 8 1.8 6 0.5 6.3 6
a Intra-time point comparisons of synonymous substitutions per pot
onsynonymous site (dn) and the ratio of synonymous to nonsynonym
ous substitution (i.e., dn 5 0) was not included in the calculation.
b Number of clones analyzed.
c P value.ifferences in the appearance of resistant mutations
mong different patients. It could be also argued that in
ivo activation of long-lived, latently infected cells (4) can
esult in HIV-1 replication and therefore account for the
ow-level plasma virion-associated RNA detected in
hese patients. Thus, the divergence in the V3 env se-
uences observed between the two time points could be
ue to the return of the pretreatment env variants by
eactivation of latently infected cells, rather than the
ccumulation of substitutions due to the ongoing viral
eplication. While this may be the case for patient C,
here env phylogenetic reconstructions showed an in-
ermingling of sequences from the two time points, the
attern observed within the env phylogenetic reconstruc-
ions of patients A and B is more compatible with a low
evel of ongoing viral replication. In agreement with the
esults presented here, lymph node analysis by in situ
ybridization of patients A and B (patient C was not
nalyzed) detected productively infected CD4 T cells
king env Regions DNA Sequencesa
Wilcoxon’s
igned rank
test
Mean dn
6 SD
Wilcoxon’s
signed rank
test
Mean ds/dn
6 SD
Wilcoxon’s
signed rank
test
0.123 4.4 6 2.0 0.001 0.3 6 0.3 ,0.001
2.1 6 2.4 2.0 6 2.1
,0.001 7.8 6 3.9 ,0.001 0.8 6 0.7 0.001
1.1 6 1.4 2.1 6 2.4
,0.001 4.8 6 2.7 ,0.001 0.6 6 0.7 ,0.001
3.2 6 2.2 2.2 6 1.8
ynonymous site (ds) and synonymous nonsubstitutions per potential
se substitutions (ds/dn). Any viral sequence that lacked a nonsynony-
ol Region DNA Sequencesa
Wilcoxon’s
igned rank
test
Mean dn
6 SD
Wilcoxon’s
signed rank
test
Mean ds/dn
6 SD
Wilcoxon’s
signed rank
test
0.554 0.6 6 0.3 0.465 8.7 6 5.5 0.609
0.6 6 0.3 8.8 6 5.2
0.033 0.8 6 0.3 ,0.001 7.3 6 4.3 0.002
0.3 6 0.2 15.0 6 8.3
0.983 0.8 6 0.4 0.390 8.8 6 4.9 0.433
0.7 6 0.3 11.5 6 7.9
ynonymous site (ds) and synonymous nonsubstitutions per potential
se substitutions (ds/dn). Any viral sequence that lacked a nonsynony-ABLE 1
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185RAPID COMMUNICATION22). Alternatively, it can not be discarded that the viral
equence difference observed in patient C at interval
ime points might be a consequence of sampling error.
Finally, our results show a statistically significant re-
uction in the genetic diversity of the viral population at
he env locus as a consequence of long-term virus sup-
ression. This result is in agreement with a recent report
y Delwart et al. (5) where a reduction in plasma viral
opulation diversity was observed in a long-term re-
ponder to ritonavir monotherapy. In contrast, no evi-
ence of env diversity reduction was found in transient
esponders to AZT (14, 24). Of interest is that this reduc-
ion PBMC env viral population is accompanied by a
wofold increase in the ds/dn ratios, suggesting that a
ifferent selection of constraints for change are present
uring this period of viral plasma suppression. The pos-
ible clinical benefit of the reduced evolutionary poten-
ial of this locus during these long periods of HIV plasma
uppression remains to be elucidated.
Materials and Methods. Patients. CD4 T-cell counts,
lasma HIV-1 RNA level, and the duration of antiretroviral
herapy are showed in Fig. 1. Virion-associated HIV-1
NA was measured by the Amplicor ultrasensitive HIV-1
NA monitor assay (Roche Molecular Systems, Inc.) that
an detect 20 HIV-1 RNA copies/ml (1, 23). Two patients,
and B, under antiretroviral therapy with 3TC, AZT, and
dI and AZT and ddC, respectively, showed a sustained
nd prolonged period of plasma viremia, with HIV RNA
evels between 20 and 200 copies/ml, for at least 24
onths (Fig. 1). Patient C, who started therapy with one
rotease inhibitor (indinavir) and two nucleoside ana-
ogues (3TC and D4T), showed a sustained viral load
elow 20 copies/ml of HIV RNA for more than 12 months
Fig. 1).
Recovery and Analysis of DNA Sequences. Proviral
equences spanning the V3 and flanking env regions
T
Oligonucleotide Primers Used f
Primer Sequence (59 to 39)
Env 1 CCAATTCCCATACATTATTG
Env 2 CAGTCTAGCAGAAGAAGA
Env 4 TTCTCCAATTGTCCCTCAT
Env 5 CTTCCTGCTGCTCCCAAGAAC
ARP828 TTTCTGGGTCCCCTCCTGAGG
RT 18 GGAAACCAAAAATGATAGGGGGAATT
RT 19 GGACATAAAGCTATAGGTACA
RT20 CTGCCAGTTCTAGCTCTGCTT
RT21 CTGTATTTCTGCTATTAAGTCTTTTG
IN5 AATTTTCCCATTAGTCCTATTGAAACT
Z2447 GTAGATTTCAGAGAACTTAAT
NE135 CCCACTAATTCTGTATGTCATTGACAG
a Numerical position on the HIV-1 HXB2 strain.nd the first 238 amino acids of the viral reverse sranscriptase (RT amplified by the PCR from blood
BMCs samples obtained at the beginning of the ther-
py and at 24 (patients A and B) and 14 months of
ntiretroviral therapy (patient C). Product DNAs from
he two regions and from the two time points were
loned, and a mean of 11 clones (Table 1 and 2) from
ach sample were sequenced. Total cell DNA was
repared by suspending 2 3 106 cryopreserved Ficoll-
anded PBMCs in 400 ml of a lysis buffer (100 mM KCl,
0 mM Tris–HCl (pH, 8.3), 2.5 mM MgCl2, 1% Tween 20,
% Nonidet P-40). The cell suspension was treated
ith proteinase K at a final concentration of 100 mg/ml.
fter 60 min at 60°C, 200 ml of 6% Instagene Matrix
BioRad) was added; following 15 min at 60°C the
roteinase K was denatured by heating the lysate at
00°C for 8 min. The V3 env and the RT pol regions
ere amplified by a nested PCR using the oligonucle-
tides Env 1,2,4,5 and RT 18,19, 20, 21, respectively
Table 3). PCR was performed as described previously
16). Fifty nanomoles of each oligonucleotide was
dded to a standard PCR mixture. Cycling parameters
ere 55 (30 s), 72 (2 min), and 95°C (30 s) for 35 cycles
ith a final extension step at 72°C for 10 min. A 5-ml
liquot was reamplified in a 100-ml reaction mix using
he same cycle profile as above. The PCR products
ere amplified from 1 mg of starting DNA. To verify V3
nv and RT pol amplification, 1/20 of the nested PCR
ixture was run on a 1.5% agarose gel. PCR products
ere purified by using the Qiaquick spin PCR purifi-
ation kit (Qiagen) and then ligated with the TA cloning
lasmid pGEM T (Promega). The molecular cloning,
igation, and small-scale plasmid preparation were
escribed elsewhere (17, 18). For each sample, be-
ween 8 and 16 clones were sequenced (Tables 1 and
) by the ABI PRISMTM dRhodamine Terminator Cycle
equencing kit (Applied Biosystems). The products of
he reactions were then analyzed on an Applied Bio-
and Cycle Sequence Analysis
Position (nt)a Orientation
6857–6877 Sense
7012–7029 Sense
7664–7646 Antisense
7806–7785 Antisense
7334–7313 Antisense
2376–2406 Sense
2453–2473 Sense
3461–3440 Antisense
3538–3508 Antisense
A 2543–2577 Sense
2771–2792 Sense
CT 3333–3299 AntisenseABLE 3
or PCR
T
C
A
GGAGG
C
ATGGG
GTACC
A
TCCAGystems 310 sequencer. Sequencing oligonucleotides
f
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186 RAPID COMMUNICATIONor the V3 and flanking env regions were Env 2 and
RP828, and, for the RT pol region, IN5, Z2447, NE135
Table 3). The amount of input DNA for the first step of
he nested PCR was determined by PCR amplification
f serial dilutions of the input DNA. At least, an input
NA copy number of 10 times the endpoint for positive
CR amplification was used to ensure that multiple
IV templates were present in each sample. In addi-
ion, endpoint dilution of PBMC DNA was carried out
efore nested PCR to make products derived from a
ingle provirus, which were directly sequenced (Fig.
). Sequences were aligned using CLUSTAL W (23).
hylogenetic reconstructions were generated by using
he neighbor-joining method in the Phylogeny Infer-
nce Package (PHYLIP) (9, 10), with a maximum like-
ihood distance matrix. Bootstrap resampling (8) was
pplied to the neighbor-joining trees to assign approx-
mate confidence limits to individual branches. The
inal graphical output was created with the program
REEVIEW (19). Sequence distances were calculated
s Hamming distances, or (1 2 s) 3 100, where s is
he fraction of shared sites in two aligned sequences.
he proportion of synonymous and nonsynonymous
ubstitutions per potential synonymous or nonsynoni-
ous sites were calculated with the program WET (6).
he distribution of DNA distances between the initial
nd final time points from each patient were subjected
o nonparametric statistical treatment using the Wil-
oxon signed rank test included in the SPSS Version
.5 software package (SPSS, Inc., Chicago, IL).
Nucleotide Sequence Accession Numbers. The 71 env
nd the 60 pol sequences have been submitted to Gen-
ank with Accession Nos. AF090554 to AF090624 and
F090625 to AF090684, respectively.
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